Kakos Christos D, Ziogas Ioannis A, Demiri Charikleia D, Esagian Stepan M, Economopoulos Konstantinos P, Moris Dimitrios, Tsoulfas Georgios, Alexopoulos Sophoclis P
Surgery Working Group, Society of Junior Doctors, 15123 Athens, Greece.
Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Cancers (Basel). 2022 Mar 2;14(5):1294. doi: 10.3390/cancers14051294.
Liver transplantation (LT) is the only potentially curative option for children with unresectable hepatocellular carcinoma (HCC). We performed a systematic review of the MEDLINE, Scopus, Cochrane Library, and Web of Science databases (end-of-search date: 31 July 2020). Our outcomes were overall survival (OS) and disease-free survival (DFS). We evaluated the effect of clinically relevant variables on outcomes using the Kaplan-Meier method and log-rank test. Sixty-seven studies reporting on 245 children undergoing LT for HCC were included. DFS data were available for 150 patients and the 1-, 3-, and 5-year DFS rates were 92.3%, 89.1%, and 84.5%, respectively. Sixty of the two hundred and thirty-eight patients (25.2%) died over a mean follow up of 46.8 ± 47.4 months. OS data were available for 222 patients and the 1-, 3-, and 5-year OS rates were 87.9%, 78.8%, and 74.3%, respectively. Although no difference was observed between children transplanted within vs. beyond Milan criteria ( = 0.15), superior OS was observed in children transplanted within vs. beyond UCSF criteria ( = 0.02). LT can yield favorable outcomes for pediatric HCC beyond Milan but not beyond UCSF criteria. Further research is required to determine appropriate LT selection criteria for pediatric HCC.
肝移植(LT)是无法切除的肝细胞癌(HCC)患儿唯一可能治愈的选择。我们对MEDLINE、Scopus、Cochrane图书馆和科学网数据库进行了系统综述(检索截止日期:2020年7月31日)。我们的研究结果是总生存期(OS)和无病生存期(DFS)。我们使用Kaplan-Meier方法和对数秩检验评估临床相关变量对研究结果的影响。纳入了67项报告245例接受LT治疗HCC患儿的研究。150例患者有DFS数据,1年、3年和5年DFS率分别为92.3%、89.1%和84.5%。238例患者中有60例(25.2%)在平均46.8±47.4个月的随访期内死亡。222例患者有OS数据,1年、3年和5年OS率分别为87.9%、78.8%和74.3%。尽管在符合米兰标准与不符合米兰标准的患儿之间未观察到差异(P=0.15),但符合加州大学旧金山分校(UCSF)标准与不符合UCSF标准的患儿相比,前者的OS更佳(P=0.02)。对于超出米兰标准但未超出UCSF标准的儿童HCC,LT可产生良好的结果。需要进一步研究以确定儿童HCC合适的LT选择标准。